During the last session, Apyx Medical Corp (NASDAQ:APYX)’s traded shares were 93253.0, with the beta value of the company hitting 1.22. At the end of the trading day, the stock’s price was $0.98, reflecting an intraday gain of 4.84% or $0.05. The 52-week high for the APYX share is $1.99, that puts it down -103.06 from that peak though still a striking 22.45% gain since the share price plummeted to a 52-week low of $0.76. The company’s market capitalization is $36.85M, and the average intraday trading volume over the past 10 days was 82210.0 shares, and the average trade volume was 41.69K shares over the past three months.
Apyx Medical Corp (APYX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.33. APYX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
Apyx Medical Corp (NASDAQ:APYX) trade information
Apyx Medical Corp (APYX) registered a 4.84% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.84% in intraday trading to $0.98, hitting a weekly high. The stock’s 5-day price performance is 10.80%, and it has moved by -10.55% in 30 days. Based on these gigs, the overall price performance for the year is -29.86%. The short interest in Apyx Medical Corp (NASDAQ:APYX) is 0.14 million shares and it means that shorts have 2.7 day(s) to cover.
The consensus price target of analysts on Wall Street is $8.5, which implies an increase of 88.47% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $12 respectively. As a result, APYX is trading at a discount of -1124.49% off the target high and -410.2% off the low.
Apyx Medical Corp (APYX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -0.15% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.39M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 12.16M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.24M and 12.15M respectively. In this case, analysts expect current quarter sales to shrink by -8.35% and then jump by 0.07% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.68%. While earnings are projected to return 37.37% in 2025, the next five years will return 18.29% per annum.
APYX Dividends
Apyx Medical Corp is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Apyx Medical Corp (NASDAQ:APYX)’s Major holders
Apyx Medical Corp insiders own 14.56% of total outstanding shares while institutional holders control 43.92%, with the float percentage being 51.40%. ARCHON CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 53.0 institutions own stock in it. As of 2024-06-30, the company held over 3.12 million shares (or 8.9923% of all shares), a total value of $4.17 million in shares.
The next largest institutional holding, with 2.5 million shares, is of ROYCE & ASSOCIATES LP’s that is approximately 7.2082% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.35 million.
Also, the Mutual Funds coming in first place with the largest holdings of Apyx Medical Corp (APYX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and ROYCE FUND-Royce Small-Cap Opportunity Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.01 shares. This amounts to just over 2.67 percent of the company’s overall shares, with a $0.99 million market value. The same data shows that the other fund manager holds slightly less at 994.78, or about 2.63% of the stock, which is worth about $0.97 million.
